|
gptkbp:instanceOf
|
gptkb:drug
farnesyltransferase inhibitor
|
|
gptkbp:ATCCode
|
L01XX41
|
|
gptkbp:bioavailability
|
high oral bioavailability
|
|
gptkbp:CASNumber
|
192185-72-1
|
|
gptkbp:clinicalTrialPhase
|
Phase II
Phase III
|
|
gptkbp:developedBy
|
gptkb:Janssen_Pharmaceutica
|
|
gptkbp:eliminatedIn
|
renal
fecal
|
|
gptkbp:eliminationHalfLife
|
~4 hours
|
|
gptkbp:hasClinicalTrialSponsor
|
gptkb:Kura_Oncology
|
|
gptkbp:hasMolecularFormula
|
C27H22Cl2N6O
|
|
gptkbp:hasOrphanDrugDesignation
|
yes (for certain cancers)
|
|
gptkbp:hasSMILES
|
CC1C(=O)N(C2=CC=CC=C12)C3=NC=NC4=C3N=CN4C(=O)NC5=CC=CC=C5Cl
|
|
gptkbp:hasTargetMutation
|
gptkb:HRAS-mutant_tumors
|
|
gptkbp:hasUNII
|
Y5L01572V8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
tipifarnib
|
|
gptkbp:indication
|
gptkb:acute_myeloid_leukemia
solid tumors
myelodysplastic syndromes
|
|
gptkbp:IUPACName
|
(S)-3-[(2,3-dichlorophenyl)methyl]-2,3,4,5-tetrahydro-2-methyl-5-oxo-1H-1,4-benzodiazepin-2-yl]-1H-imidazo[4,5-b]pyridine-2-carboxamide
|
|
gptkbp:legalStatus
|
patented
investigational (not FDA approved as of 2024)
|
|
gptkbp:mechanismOfAction
|
inhibits farnesyltransferase
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
517.41 g/mol
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL19020
gptkb:DB00525
148192
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
fatigue
rash
myelosuppression
|
|
gptkbp:status
|
investigational
not FDA approved (as of 2024)
|
|
gptkbp:synonym
|
gptkb:R115777
gptkb:Zarnestra
|
|
gptkbp:target
|
gptkb:farnesyltransferase
|
|
gptkbp:therapeuticArea
|
oncology
|
|
gptkbp:bfsParent
|
gptkb:Harvey_rat_sarcoma_viral_oncogene_homolog
|
|
gptkbp:bfsLayer
|
6
|